Trial · NCT04732949
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Hospital Discharge | Day 28 | The Intent-to-Treat (ITT) analysis population consisted of all randomised patients. | days | MEDIAN |
| PRIMARY | Time to Recovery | Day 28 | The ITT analysis population consisted of all randomised patients. | days | MEDIAN |
| SECONDARY | Number of Patients Who Progressed to Severe Disease or Death | Until Day 35 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients Who Were Intubated or Who Died | Until Day 35 | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients Who Died Within 35 Days of First Dose | Until Day 35 of first dose | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cumulative Number of Patients Who Were Discharged From Hospital | Days 7, 14, 21 and 28 | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cumulative Number of Patients With Recovery | Days 7, 14, 21 and 28 | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Improvement Based on Entire WHO OSCI Score | Until Day 35 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change From Baseline in Total Score According to the Breathlessness, Cough and Sputum Scale (BCSS) | Baseline to Day 15 | The ITT analysis population consisted of all randomised patients. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in National Early Warning Score (NEWS2) During the Hospitalisation Period | Day 1 until Day 28 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Number of Patients With Presence of COVID-19 Symptoms Based on Daily Assessment | Day 1 until Day 90 | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Limitations of Usual Activities Based on Daily Assessment | Day 1 until Day 35 | The ITT analysis population consisted of all randomised patients. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Quality of Life Measured Using EuroQol 5-dimension 5-level (EQ-5D-5L) | Day 0, Day 7, Day 15, Day 28, Day 60 and Day 90 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | General Anxiety Disorder 7 Questionnaire (GAD-7) Total Score | Day 15, Day 28, Day 60 and Day 90 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-FS [Version 4]) Total Score | Day 15, Day 28, Day 60 and Day 90 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Patient Health Questionnaire-9 (PHQ-9) Total Score | Day 15, Day 28, Day 60 and Day 90 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Overall Pain Severity as Measured by Brief Pain Inventory Composite Scores | Day 15, Day 28, Day 60 and Day 90 | The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From the day informed consent is obtained until 28 days after the last administration of the study medication (Day 90) | The Safety analysis population included all patients in the ITT population who receive at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04732949/outcomes